Send to

Choose Destination
Perspect Clin Res. 2019 Apr-Jun;10(2):95-99. doi: 10.4103/picr.PICR_126_18.

Authoring a periodic adverse drug experience report…here's what you need to know!

Author information

Scientific Writing and Communications, Siro Clinpharm Pvt. Ltd., Thane, Maharashtra, India.
Life Sciences Learning and Development Professional, Maharashtra, India.


Aggregate reporting involves preparation and submission of safety reports for a given medicinal product to worldwide regulatory agencies and constitutes an essential part of safety monitoring of a medicinal product. There are specific aggregate safety reports required for a molecule in development called development safety update reports while Periodic Adverse Drug Experience Reports (PADERs) and Periodic Safety Update Reports/Periodic Benefit-risk Evaluation Reports (PBRERs) are submitted for products with marketing authorization. Based on the periodic analysis of worldwide safety reports, product label is updated to optimize safe use of a medicinal product. PADERs are aggregate safety reports to be submitted to the Food and Drug Administration (FDA) for products approved for marketing in the United States (US). PADER submission starts once marketing authorization approval is received for a medicinal product by the sponsor. Quarterly and annual PADERs should be submitted within 30 and 60 days of data lock point, respectively. PADERs mainly involve presentation of case reports with serious unlisted events (15-day alert reports) in the form of narratives or in a tabular format. The present article focuses on the background, scope, structure of a PADER, and its submission timelines; lists differences between PADER and PBRER; and describes the knowledge, skills, and attitudes required for a PADER writer.


Periodic Adverse Drug Experience Report; Periodic Benefit-risk Evaluation Report; Periodic Safety Update Report; pharmacovigilance

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center